Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

University of Ottawa

$105,000.00

Investigating the effects of recombinant human collagen hydrogel injection on heart function and infarct repair post-myocardial infarction.

FY 2016-17

Summary
Following a heart attack, or myocardial infarction (MI), progression to heart failure occurs in 10% of patients even with current surgical and pharmaceutical interventions. Heart failure is incurable and has a 50% five-year mortality rate. Heart failure occurs due to the limited capacity of the heart to regenerate or repair itself after injury, which leads to pathological remodeling of the ventricular chambers that reduces blood pumping efficiency. A key component of this remodeling process is the degradation and modification of the cardiac extracellular matrix (ECM) post-MI. The cardiac ECM is primarily composed of type I and type III collagen protein fibers that support the cardiac tissue and also mediate tissue homeostasis and repair. Collagen-based hydrogels are biomaterials that are produced to mimic the native cardiac ECM and have shown promise to preserve heart function post-MI. However, all of the biomaterial therapies tested to date have not been of human origin, which limits their clinical translation. Our group has produced the first recombinant human collagen type I and type III hydrogels (rHCI and rHCIII). It was observed that rHCI injection post-MI improved heart function after 4 weeks compared to baseline prior to injection, while rHCIII injection maintained heart function and non-treated animals showed a reduction in heart function. My hypothesis is that the mechanical support provided by these hydrogels as well as by-products of their degradation provides both structural support and activates signaling pathways involved in increasing vascular density and improving inflammation resolution in the infarct. For my doctoral work I will focus on the optimization of rHC hydrogel treatment as well as investigating the mechanism of action of this treatment in a mouse MI model. This research is anticipated to direct the clinical translation of the first recombinant human biomaterial therapy for heart failure prevention.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
365505
Name
McLaughlin Sarah
Region
Ontario
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating the effects of recombinant human collagen hydrogel injection on heart function and infarct repair post-myocardial infarction.
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Collagen Hydrogels; Heart Failure; Myocardial Infarction; Recombinant Human Collagen; Regenerative Medicine
Abstract
Following a heart attack, or myocardial infarction (MI), progression to heart failure occurs in 10% of patients even with current surgical and pharmaceutical interventions. Heart failure is incurable and has a 50% five-year mortality rate. Heart failure occurs due to the limited capacity of the heart to regenerate or repair itself after injury, which leads to pathological remodeling of the ventricular chambers that reduces blood pumping efficiency. A key component of this remodeling process is the degradation and modification of the cardiac extracellular matrix (ECM) post-MI. The cardiac ECM is primarily composed of type I and type III collagen protein fibers that support the cardiac tissue and also mediate tissue homeostasis and repair. Collagen-based hydrogels are biomaterials that are produced to mimic the native cardiac ECM and have shown promise to preserve heart function post-MI. However, all of the biomaterial therapies tested to date have not been of human origin, which limits their clinical translation. Our group has produced the first recombinant human collagen type I and type III hydrogels (rHCI and rHCIII). It was observed that rHCI injection post-MI improved heart function after 4 weeks compared to baseline prior to injection, while rHCIII injection maintained heart function and non-treated animals showed a reduction in heart function. My hypothesis is that the mechanical support provided by these hydrogels as well as by-products of their degradation provides both structural support and activates signaling pathways involved in increasing vascular density and improving inflammation resolution in the infarct. For my doctoral work I will focus on the optimization of rHC hydrogel treatment as well as investigating the mechanism of action of this treatment in a mouse MI model. This research is anticipated to direct the clinical translation of the first recombinant human biomaterial therapy for heart failure prevention.
Competitiondate
201610
Approvedterm2
3 yrs 0 mth
Pinamesdelim
McLaughlin, Sarah
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
University of Ottawa - $105,000 Grant (2016-17) | Canada Spends